Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs

Author(s): Karina Vázquez, Margot Paulino, Cristian O. Salas, Juan J. Zarate-Ramos, Brenda Vera, Gildardo Rivera*.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 17 , Issue 11 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Background & Objective: Chagas disease or American trypanosomiasis is a major parasitic disease in Latin America with restricted available treatment: nifurtimox and benznidazole. These two drugs are ineffective in the chronic phase of the disease; therefore, there is a need for the development of new, efficient and safe drugs for the treatment of this pathology. With this goal, one of the promising targets is trypanothione reductase (TR), a key enzyme in the metabolism of Trypanosoma cruzi.

Conclusion: In this review, we analyse the importance of TR as a drug target, as well as the well-known and new inhibitors reported in the last decade as potential therapeutic agents for Chagas disease.

Keywords: Chagas disease, trypanothione reductase, Trypanosoma cruzi, target, drugs, inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [939 - 946]
Pages: 8
DOI: 10.2174/1389557517666170315145410
Price: $58

Article Metrics

PDF: 31